Siegfried : Announces Change in its Board of Directors
September 29, 2022 at 01:24 am EDT
Share
Ad hoc announcement pursuant to Art. 53 Listing Rules
Zofingen, 29 September 2022
Siegfried Announces Change in its Board of Directors
After 10 years on the Board of Directors of the Siegfried Group, Board member Colin Bond has decided not to stand for re-election at the company's upcoming Annual General Meeting (AGM) on 20 April 2023.
As his successor, the Board of Directors has nominated Elodie Cingari (48) as new member for election.
"We are very pleased to nominate Elodie Cingari to Siegfried's Board of Directors," said Andreas Casutt, Chairman of the Board. "Her extensive professional experience and a profound knowledge in finance makes her an ideal person for this role. At the same time, I would like to thank Colin Bond for his outstanding contributions to our work. Colin has been Chairman of the Audit Committee and offered years of long-standing service for which we are very grateful."
Elodie Cingari has been the Chief Financial Officer of the Landis+Gyr Group since 2020. Previously she held the positon of Chief Financial Officer of the Hoerbiger Group. Prior to that, Elodie Cingari spent 11 years with Alstom and later General Electric following the Alstom acquisition, where she held several CFO positions of global businesses in the Energy and Grid sectors. She spent the first 10 years of her career with Hewlett-Packard where she held different finance leadership roles.
Contact
Media:
Financial Analysts:
Peter Stierli
Dr. Reto Suter
Head Corporate Communications
Chief Financial Officer
Tel. +41 62 746 15 51
Tel. +41 62 746 11 35
peter.stierli@siegfried.ch
reto.suter@siegfried.ch
Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen
1
This media release on the web
www.siegfried.ch/media-releases
About Siegfried
The Siegfried Group is a global life sciences company with a network of 11 sites in Europe, the USA and Asia. Siegfried offers contract developing and manufacturing of pharmaceutical APIs, intermediates, as well as drug products. In 2021, Siegfried achieved sales of 1.1 billion Swiss francs and more than 3'600 employees. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
Siegfried Holding AG published this content on 29 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 September 2022 05:23:06 UTC.
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.